Altimmune, Inc.
ALT
Rank in Stocks
#13136
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on... Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Share Price
$2.12
Last synced: 2026-11-09
Market Cap
$412.38M
Change (1 day)
1.92%
Change (1 year)
-50.47%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Altimmune, Inc. (ALT)
Category
Healthcare
EPS for Altimmune, Inc. (ALT)
EPS as of June 2026 TTM: $-0.78
According to Altimmune, Inc.'s latest financial reports, its current EPS (TTM) is $-0.78. At the end of 2025 the company had an EPS of $-1.00, an increase over its 2024 EPS of $-1.34.
EPS history for Altimmune, Inc. from 2005 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.78 | -22.00% |
| 2025 | $-1.00 | -25.37% |
| 2024 | $-1.34 | -19.28% |
| 2023 | $-1.66 | -8.29% |
| 2022 | $-1.81 | -22.98% |
| 2021 | $-2.35 | 23.04% |
| 2020 | $-1.91 | 22.44% |
| 2019 | $-1.56 | -88.84% |
| 2018 | $-13.98 | -87.15% |
| 2017 | $-108.77 | 118.41% |
| 2016 | $-49.80 | 208.74% |
| 2015 | $-16.13 | -68.93% |
| 2014 | $-51.91 | -25.20% |
| 2013 | $-69.40 | 127.17% |
| 2012 | $-30.55 | 26.92% |
| 2011 | $-24.07 | -92.56% |
| 2010 | $-323.59 | -7.86% |
| 2009 | $-351.19 | -26.24% |
| 2008 | $-476.15 | 10.30% |
| 2007 | $-431.69 | -1,926.87% |
| 2006 | $23.63 | 96.92% |
| 2005 | $12.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,107.69% |
US
|
|
| $-7.07 | 806.41% |
US
|
|
| $-5.29 | 578.21% |
AU
|
|
| $12.88 | -1,751.29% |
BE
|
|
| $21.56 | -2,864.10% |
NL
|
Questions about Altimmune, Inc.'s earnings per share (EPS)
What is Altimmune, Inc.'s earnings per share (EPS)?
Altimmune, Inc.'s earnings per share (EPS) over the last twelve months is $-0.78, as of Jun 2026.
What was Altimmune, Inc.'s earnings per share (EPS) in 2025?
In 2025, Altimmune, Inc.'s earnings per share (EPS) was $-1.00, compared with $-1.34 in 2024.
How has Altimmune, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Altimmune, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.00) and lowest in 2021 ($-2.35).
How does Altimmune, Inc.'s earnings per share (EPS) compare with similar companies?
Altimmune, Inc.'s earnings per share (EPS) ($-0.78) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.